Zevra Therapeutics (ZVRA) Research & Development (2014 - 2026)

Zevra Therapeutics has reported Research & Development for 13 years, with the latest figure at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 34.81% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.9 million (down 58.05% YoY), and the FY2025 full-year result was $12.7 million, down 69.73% from the prior year.
• Research & Development for Q1 2026 stood at $4.4 million, up from $2.6 million in the prior quarter.
• The five-year high for Research & Development was $12.3 million in Q3 2023, with the low at $2.6 million in Q4 2025.
• Historically, Research & Development has averaged $7.2 million across 5 years, with a median of $7.0 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development jumped 140.51% — and 2025, when it tumbled 73.46%.
• Zevra Therapeutics' Research & Development stood at $6.5 million in 2022, then surged by 74.61% to $11.4 million in 2023, then declined by 26.87% to $8.4 million in 2024, then slumped by 68.63% to $2.6 million in 2025, then surged by 67.63% to $4.4 million in 2026.
• The last three Research & Development figures came in at $4.4 million (Q1 2026), $2.6 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.